|

Ofatumumab Clinical Trials

5 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • Third Affiliated Hospital, Sun Yat-Sen University1
  • The First People's Hospital of Changzhou1
  • Biogen1

Indications

Other2 trials

Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Phase 3

Houston, Texas2 trials

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M D Anderson Cancer Center

Phase 2

Eden Prairie, Minnesota1 trial

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

OptumInsight

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.